RespireRx Pharmaceuticals Inc. to Present at Noble Financial Capital Markets' Twelfth Annual Investor/Equity Conference - Nob...
January 19 2016 - 8:00AM
Marketwired
RespireRx Pharmaceuticals Inc. to Present at Noble Financial
Capital Markets' Twelfth Annual Investor/Equity Conference -
NobleCon12
GLEN ROCK, NJ-(Marketwired - Jan 19, 2016) - RespireRx
Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"),
a leader in developing drugs for respiratory disorders,
particularly sleep apneas and drug-induced respiratory depression,
announces that the Company's Vice President, Treasurer and
Secretary and member of the Board of Directors, Jeff Margolis will
present at the Noble Financial Capital Markets' Twelfth Annual
Investor/Equity Conference - NobleCon12 on Wednesday, January 20,
2016 at 10:30 AM Eastern Standard Time
(http://nobleconference.com/general-agenda). The Conference is
sponsored by Noble Financial Capital Markets and will be held at
the Sandpiper Bay Club Med facility in Port St. Lucie, Florida from
January 17 - 20, 2016.
Mr. Margolis will discuss RespireRx's initiatives with
dronabinol for obstructive sleep apnea (Phase - 2B), CX-1739 (oral)
for drug-induced respiratory depression and central sleep apnea
(both Phase - 2A). He will also provide background information and
descriptions of other product pipeline candidates.
Mr. Margolis' presentation will be available by live webcast
streaming online and will also be archived. To access the live
audio webcast, log onto the RespireRx website at www.respirerx.com,
click on the investors tab and follow the links and instructions,
or go to
http://noble.mediasite.com/mediasite/Play/2fffb581d269487ca511a4cb740447051d.
A copy of the slide presentation to be presented at the conference
will be submitted in a filing by the Company with the U.S.
Securities and Exchange Commission in a Current Report on Form 8-K
prior to the presentation and will also be available in the
investors section of the RespireRx website.
Comments by the Company's Vice President, Treasurer and
Secretary Jeff Margolis, RespireRx Vice President, Treasurer and
Secretary, commented, "We are looking forward to the opportunity to
present our strategic and operational goals for 2016 at the
upcoming Noble Conference. Management will continue to update
shareholders and other stakeholders on the progress of RespireRx's
scientific, clinical and regulatory development initiatives during
2016."
About RespireRx Pharmaceuticals Inc. RespireRx Pharmaceuticals
Inc. is a leader in the development of drugs for respiratory
disorders, with a focus on sleep apneas and drug-induced
respiratory depression. The Company holds exclusive licenses and
owns patents and patent applications for certain families of
chemical compounds that claim the chemical structures and their use
in the treatment of a variety of disorders, as well as claims for
novel uses of known drugs.
RespireRx's pharmaceutical candidates in development are derived
from two platforms, as described below.
The first platform is the class of compounds known as
cannabinoids, in particular, dronabinol. Under a license agreement
with the University of Illinois, the Company has rights to patents
claiming the use of cannabinoids for the treatment of sleep-related
breathing disorders. In a double-blind, placebo-controlled,
dose-ascending Phase 2A clinical study conducted by the Company,
dronabinol produced a statistically significant reduction in the
Apnea-Hypopnea Index, the primary therapeutic end-point, and was
observed to be safe and well-tolerated in a group of patients with
Obstructive Sleep Apnea ("OSA"). The University of Illinois and
three other centers currently are investigating dronabinol in a
potentially pivotal, six week, double-blind, placebo-controlled
Phase 2B clinical trial in 120 patients with OSA. This study, which
the University of Illinois has indicated it expects to be completed
during the second quarter of 2016, is fully funded by the National
Heart, Lung and Blood Institute of the National Institutes of
Health. The Company is not managing or funding this ongoing
clinical trial.
The second platform of medicines being developed by RespireRx is
a class of proprietary compounds known as ampakines, which act to
enhance the actions of the excitatory neurotransmitter glutamate at
AMPA glutamate receptors. Several ampakines, in both oral and
injectable form, are being developed by the Company for the
treatment of a variety of breathing disorders. In clinical studies,
select ampakines have shown preliminary efficacy in central sleep
apnea and in the control of respiratory depression produced by
opiates, without altering their analgesic effects. In animal models
of orphan disorders, such as Pomp Disease, spinal cord damage and
perinatal respiratory distress, it has been demonstrated that
certain ampakines improve breathing function. The Company's
compounds belong to a new class of ampakines that do not display
the undesirable side effects previously reported in animal models
of earlier generations.
Additional information about the Company and the matters
discussed herein can be obtained on the Company's web-site at
www.RespireRx.com or in the Company's filings with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov.
Special Note Regarding Forward-Looking Statements: Certain
statements included or incorporated by reference in this news
release, including information as to the future financial or
operating performance of the Company and its drug development
programs, constitute forward-looking statements. The words
"believe," "expect," "anticipate," "contemplate," "target," "plan,"
"intend," "continue," "budget," "estimate," "may," "schedule" and
similar expressions identify forward-looking statements.
Forward-looking statements include, among other things, statements
regarding future plans, targets, estimates and assumptions.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Many factors could
cause the Company's actual results to differ materially from those
expressed or implied in any forward-looking statements made by, or
on behalf of, the Company. Due to these various risks and
uncertainties, actual events may differ materially from current
expectations. Investors are cautioned that forward-looking
statements are not guarantees of future performance and,
accordingly, investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Forward-looking statements are made as of the date of this news
release and the Company disclaims any intent or obligation to
update publicly such forward-looking statements, whether as a
result of new information, future events or results or
otherwise.
Contact Information
- Company Contact: Jeff Margolis Vice-President, Treasurer and
Secretary Telephone: (917) 834-7206 E-mail: jmargolis@respirerx.com
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024